ERBB2 and breast carcinoma: In a study that explored the possibility of inhibiting Notch signaling to overcome trastuzumab resistance [101], it was found that combined inhibition of Notch and HER2 signaling pathways can indeed decrease recurrence rates for breast cancers that are characterized by HER2 overexpression.